The use of middle cerebral artery (MCA) angioplasty compared with drug therapy has been controversial. Few studies have reported the correlations between cognitive function improvement and MCA angioplasty. This study aimed to explore neurocognitive function after angioplasty in patients with middle cerebral artery stenosis (MCAS) and objective cerebral ischemia. We identified 14 patients diagnosed with MCAS aged 45-65 years. Neurocognitive function evaluation was performed by 2 independent clinical psychologists using the Mini-Mental State Examination (MMSE), Montreal cognitive assessment scale (MoCA), and Multi-Dimensional Psychology. All patients received general anesthesia, underwent diagnostic cerebral angiography (DSA) via the femoral route and angioplasty, and then were sent to the neurologic intensive care unit (NICU) for overnight hemodynamic and neurologic monitoring. Aspirin and clopidogrel treatments were continued for 3 months after successful intervention. Complete neurologic examinations, innd significant improvements in the MMSE, 3-dimensional (3D) mental rotation, simple calculation, and spatial working memory. In the recurrent stenosis group, we found no statistically significant changes in cognitive function compared with the baseline and after a 6-month follow up. There were high correlations between the changes in perfusion and the changes in word and picture memory. There was a significant correlation between the change in perfusion with MMSE (-0.522), spatial working memory (0.655), and Raven's progressive matrices test (0.637); a moderate correlation with 3D rotation (0.413), and simple calculation (-0.359); and weak correlation with visual tracking (0.026) and MoCA (0.279). Angioplasty surgery significantly improves neurocognitive function in patients with middle cerebral artery stenosis (MCAS) and objective cerebral ischemia. Angioplasty surgery significantly improves neurocognitive function in patients with middle cerebral artery stenosis (MCAS) and objective cerebral ischemia. Therapeutic options for patients with second lung tumor (SLT) after previous pneumonectomy for lung cancer are sparsely reported and controversial. This study aims to compare the short- and long-term outcomes of different treatment patterns in patient with resectable postpneumonectomy SLT. Patients received previous pneumonectomy and subsequently occurred resectable SLT were extracted from the Surveillance, Epidemiology, and End Results (SEER) database [1998-2016]. Treatment related mortality was compared using the Pearson chi-square test. Univariate and multivariate Cox regression analyses were performed to identify the independent prognostic factors for cancer-specific survival (CSS) and overall survival (OS). Ninety-nine patients met the selection criteria with 5-year CSS and OS rates of 60.8% and 53.7%, respectively 23 patients received no lung resection (nLR) and 76 patients received lung resection (LR). There was no statistically significant difference between nLR group and LR group in both treatment related mortality (0.0% vs. 2.6%, P=0.432), CSS (58.3% vs. 61.7%, P=0.633) and OS (55.3% vs. 53.3%, P=0.635). Patients with subsequent adenocarcinoma (P=0.001) and smaller tumor size of SLT (P<0.001) were more likely to receive LR treatment. In the LR subgroup analysis, patients received sublobar resection (SLR) had better CSS [hazard ratio (HR) 0.381, 95% confidence interval (CI) 0.176-0.827, P=0.030] and OS (HR 0.562, 95% CI 0.287-1.100, P=0.051) than those received lobectomy. SLR or non-surgical resection is reasonable therapeutic option for patients with resectable SLT after previous pneumonectomy to achieve long-term survival, with acceptable treatment related mortality. SLR or non-surgical resection is reasonable therapeutic option for patients with resectable SLT after previous pneumonectomy to achieve long-term survival, with acceptable treatment related mortality. The coronavirus disease 2019 (COVID-19) pandemic continues to grow worldwide, and systematic reviews (SRs)/meta-analyses (MAs) on COVID-19 can efficiently guide evidence-based clinical practice. However, SRs/MAs with weaknesses can mislead clinical practice and pose harm to patients, and too many useless SRs/MAs could pose confusion and waste sources. A "living" overview of SRs/MAs aims to provide an open, accessible and frequently updated resource summarizing the highest-level evidence of COVID-19, that can help evidence-users to quickly identify trusted evidence to guide the practice. This study aims to systematically give an overview SRs/MAs of COVID-19, assess their quality, and identify the best synthesis of evidence. Databases including Medline, EMBASE, Web of Science, China National Knowledge Infrastructure (CNKI), China Biology Medicine (CBM) and WanFang were systematically searched on May 1, 2020 using relevant terms for identify SRs/MAs related to COVID-19. The study selection, data extraction acape on prevalence, prevention, diagnosis, treatment, and prognosis of COVID-19. In this study, we will present for the first time, an overview of SRs/MAs, which provides a comprehensive, dynamic evidence landscape on prevalence, prevention, diagnosis, treatment, and prognosis of COVID-19.Acute myocardial infarction has been reported to be a common clinical complication after renal transplantation. This case report involves a retrospective review of the clinical management of a 56-year-old woman with a history of renal transplantation, who developed acute myocardial infarction and was treated with percutaneous coronary intervention and anti-coagulation therapy. After the treatment of percutaneous coronary intervention and anti-coagulation therapy, she was then readmitted to the hospital with upper gastrointestinal bleeding, renal calculus formation, and subsequent kidney injury. https://www.selleckchem.com/products/mk571.html The unique of this case is that we encountered a patient who had acute myocardial infarction after renal transplantation with percutaneous coronary intervention treatment, with complications involving renal calculus formation and upper gastrointestinal bleeding. And we outline the risk factors of complications and the risk factors of antirejection and anti-coagulant drug therapies that had been prescribed to manage her renal transplantation and acute myocardial infarction.